HLB Pharmaceutical (Korea) Performance
| 047920 Stock | KRW 25,850 1,750 6.34% |
On a scale of 0 to 100, HLB Pharmaceutical holds a performance score of 7. The company owns a Beta (Systematic Risk) of 1.25, which attests to a somewhat significant risk relative to the market. As the market goes up, the company is expected to outperform it. However, if the market returns are negative, HLB Pharmaceutical will likely underperform. Please check HLB Pharmaceutical's market risk adjusted performance, semi deviation, coefficient of variation, as well as the relationship between the mean deviation and downside deviation , to make a quick decision on whether HLB Pharmaceutical's current price history will revert.
Risk-Adjusted Performance
OK
Weak | Strong |
Compared to the overall equity markets, risk-adjusted returns on investments in HLB Pharmaceutical Co are ranked lower than 7 (%) of all global equities and portfolios over the last 90 days. Despite somewhat weak basic indicators, HLB Pharmaceutical sustained solid returns over the last few months and may actually be approaching a breakup point. ...more
| Total Cashflows From Investing Activities | -15.8 B |
HLB |
HLB Pharmaceutical Relative Risk vs. Return Landscape
If you would invest 2,320,000 in HLB Pharmaceutical Co on December 19, 2024 and sell it today you would earn a total of 440,000 from holding HLB Pharmaceutical Co or generate 18.97% return on investment over 90 days. HLB Pharmaceutical Co is generating 0.3957% of daily returns and assumes 4.2531% volatility on return distribution over the 90 days horizon. Simply put, 37% of stocks are less volatile than HLB, and 93% of all equity instruments are likely to generate higher returns than the company over the next 90 trading days. Expected Return |
| Risk |
HLB Pharmaceutical Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for HLB Pharmaceutical's investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as HLB Pharmaceutical Co, and traders can use it to determine the average amount a HLB Pharmaceutical's price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = 0.093
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | 047920 | |||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns |
Estimated Market Risk
| 4.25 actual daily | 37 63% of assets are more volatile |
Expected Return
| 0.4 actual daily | 7 93% of assets have higher returns |
Risk-Adjusted Return
| 0.09 actual daily | 7 93% of assets perform better |
Based on monthly moving average HLB Pharmaceutical is performing at about 7% of its full potential. If added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of HLB Pharmaceutical by adding it to a well-diversified portfolio.
HLB Pharmaceutical Fundamentals Growth
HLB Stock prices reflect investors' perceptions of the future prospects and financial health of HLB Pharmaceutical, and HLB Pharmaceutical fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on HLB Stock performance.
| Return On Equity | -11.39 | |||
| Return On Asset | 0.0219 | |||
| Profit Margin | 0.01 % | |||
| Operating Margin | 0.04 % | |||
| Current Valuation | 216.14 B | |||
| Shares Outstanding | 13.85 M | |||
| Price To Sales | 5.60 X | |||
| Revenue | 62.85 B | |||
| EBITDA | 3.08 B | |||
| Cash And Equivalents | 6.64 B | |||
| Total Debt | 2.14 B | |||
| Debt To Equity | 0.74 % | |||
| Cash Flow From Operations | (1.32 B) | |||
| Total Asset | 127.63 B | |||
About HLB Pharmaceutical Performance
By analyzing HLB Pharmaceutical's fundamental ratios, stakeholders can gain valuable insights into HLB Pharmaceutical's financial health, operational efficiency, and overall profitability, helping them make informed investment and management decisions. For instance, if HLB Pharmaceutical has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if HLB Pharmaceutical has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements.
HLB Pharmaceutical Co., Ltd, a pharmaceutical company, develops peptide drugs in South Korea. HLB Pharmaceutical Co., Ltd was founded in 1998 and is headquartered in Namyangju, South Korea. HLBPHARMA is traded on Korean Securities Dealers Automated Quotations in South Korea.Things to note about HLB Pharmaceutical performance evaluation
Checking the ongoing alerts about HLB Pharmaceutical for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for HLB Pharmaceutical help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| HLB Pharmaceutical had very high historical volatility over the last 90 days | |
| The company reported the revenue of 62.85 B. Net Loss for the year was (13.23 B) with profit before overhead, payroll, taxes, and interest of 18.04 B. | |
| HLB Pharmaceutical Co has accumulated about 6.64 B in cash with (1.32 B) of positive cash flow from operations. | |
| Roughly 26.0% of the company shares are owned by insiders or employees |
- Analyzing HLB Pharmaceutical's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether HLB Pharmaceutical's stock is overvalued or undervalued compared to its peers.
- Examining HLB Pharmaceutical's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating HLB Pharmaceutical's management team can have a significant impact on its success or failure. Reviewing the track record and experience of HLB Pharmaceutical's management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of HLB Pharmaceutical's stock. These opinions can provide insight into HLB Pharmaceutical's potential for growth and whether the stock is currently undervalued or overvalued.
Complementary Tools for HLB Stock analysis
When running HLB Pharmaceutical's price analysis, check to measure HLB Pharmaceutical's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy HLB Pharmaceutical is operating at the current time. Most of HLB Pharmaceutical's value examination focuses on studying past and present price action to predict the probability of HLB Pharmaceutical's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move HLB Pharmaceutical's price. Additionally, you may evaluate how the addition of HLB Pharmaceutical to your portfolios can decrease your overall portfolio volatility.
| Share Portfolio Track or share privately all of your investments from the convenience of any device | |
| Stock Tickers Use high-impact, comprehensive, and customizable stock tickers that can be easily integrated to any websites | |
| AI Portfolio Architect Use AI to generate optimal portfolios and find profitable investment opportunities | |
| Portfolio Center All portfolio management and optimization tools to improve performance of your portfolios | |
| Bond Analysis Evaluate and analyze corporate bonds as a potential investment for your portfolios. | |
| Pair Correlation Compare performance and examine fundamental relationship between any two equity instruments | |
| Headlines Timeline Stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity | |
| Price Transformation Use Price Transformation models to analyze the depth of different equity instruments across global markets | |
| Content Syndication Quickly integrate customizable finance content to your own investment portal |